Abstract
Last month the American Psychiatric Association (APA) issued a position statement on psychedelics warning about the short‐ and long‐term risks of these unapproved drugs. Sanctioned by the APA board of trustees, the “Position Statement on the Use of Psychedelic and Empathogenic Agents for Mental Health Conditions” notes that preliminary research involving psychedelics for the treatment of serious conditions, such as treatment‐resistant depression and post‐traumatic stress disorder, have motivated growing interest in the therapeutic potential of these agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
